GlassScriptPhysician profile
Rey T Villanobos
NPI 1023049558
$9,998.31
in general payments reported to CMS, 2019-2025
39 companies · $2,099 in 2025
The $2,099 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,239 · 2020: $1,121 · 2021: $1,158 · 2022: $1,437 · 2023: $1,392 · 2024: $1,552 · 2025: $2,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,945 · Gift: $59.40 · Education: $39.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,944.76 |
| Gift | $59.40 |
| Education | $39.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,745.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,260.97 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Astrazeneca Pharmaceuticals LP | $754.76 | 2019-2024 | Farxiga, Lokelma |
| Corcept Therapeutics | $743.18 | 2021-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $625.76 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $583.17 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $561.13 | 2019-2025 | Jardiance |
| Recordati_rare_diseases_inc. | $408.47 | 2024-2025 | Isturisa, Signifor Lar |
| Abbott Laboratories | $371.63 | 2019-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $340.94 | 2019-2022 | |
| Mannkind Corporation | $334.48 | 2019-2024 | Afrezza |
| Intuity Medical INC | $270.68 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Abbvie INC. | $262.84 | 2019-2025 | Synthroid |
| Cequr Corporation | $169.70 | 2021-2025 | Cequr Simplicity |
| Amneal Pharmaceuticals LLC | $158.28 | 2019-2025 | Unithroid |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $153.55 | 2021-2025 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $147.73 | 2019-2025 | Tirosint, Licart, Flector |
| Xeris Pharmaceuticals, INC. | $121.44 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Novartis Pharmaceuticals Corporation | $111.47 | 2023-2025 | |
| Medtronic Minimed, INC. | $107.04 | 2019-2020 | |
| Amarin Pharma, INC. | $100.87 | 2020-2023 | |
| Amgen INC. | $84.06 | 2019-2022 | |
| Medtronic, INC. | $69.35 | 2024-2025 | Minimed 780g |
| Ascensia Diabetes Care US INC. | $68.60 | 2025 | |
| Lifescan, INC. | $54.69 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $49.65 | 2021-2024 | Strensiq |
| Ultragenyx Pharmaceutical INC. | $41.66 | 2020-2022 | |
| Ascendis Pharma Endocrinology INC | $40.06 | 2025 | Yorvipath |
| Kowa Pharmaceuticals America, INC. | $39.39 | 2019 | |
| Insulet Corporation | $38.13 | 2024-2025 | Omnipod |
| Janssen Pharmaceuticals, INC | $33.42 | 2020 | |
| Boston Scientific Corporation | $29.06 | 2025 | Apollo Esg System |
| Esperion Therapeutics, INC. | $28.04 | 2021-2024 | Nexletol |
| Madrigal Pharmaceuticals | $18.14 | 2025 | Rezdiffra |
| Kyowa Kirin, INC. | $17.25 | 2024 | Crysvita |
| Aytu Biopharma, INC. | $14.82 | 2019 | |
| Antares Pharma, INC. | $14.30 | 2025 | Xyosted |
| Zealand Pharma US, INC. | $12.65 | 2021 | |
| Clarus Therapeutics INC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rey Villanobos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.